Catalyst Pharmaceutical Partners, Inc. is a development-stage biotechnology company, which focuses on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy. The company has currently two products under development. The lead product candidate is CPP-109 (its version of vigabatrin, a GABA aminotransferase inhibitor), which is designed for the treatment of cocaine addiction. The company's second product candidate, CPP-115, another GABA aminotransferase inhibitor, is the early stages of developing. It is developed for both epilepsy (specifically,...
read more
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) has been on the progressive move since end of November. On Friday, the stock added the next 0.94% to its price, while its traded volume remained high. Though, that's not the end of the story yet.read more
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) stock surged 46.67% up on Friday already at market open and closed at $1.32 for a share. PR activity and investor alerts came again into play, as the company needs an optimistically minded market in order to be able to proceeds with its business plans.read more
CPRX, Catalyst Pharmaceutical Partners, Inc.
** CPRX reported that a poster presentation demonstrating that CPP-115, CPRX's next-generation GABA aminotransferase inhibitor, suppresses infantile spasms (IS) in the rat multiple-hit model will be made on December 3, 2011 at the American Epilepsy Society's 65th Annual Meeting (AES) to be held December 2-6, 2011 at the Baltimore Convention Center in Baltimore, Maryland.
The American read more
CPRX, Catalyst Pharmaceutical Partners, Inc.
** CPRX reported that a poster presentation demonstrating that CPP-115, CPRX's next-generation GABA aminotransferase inhibitor, suppresses infantile spasms (IS) in the rat multiple-hit model will be made on December 3, 2011 at the American Epilepsy Society's 65th Annual Meeting (AES) to be held December 2-6, 2011 at the Baltimore Convention Center in Baltimore, Maryland.
The American read more
CPRX, Catalyst Pharmaceutical Partners, Inc.
** CPRX reported that a poster presentation demonstrating that CPP-115, CPRX's next-generation GABA aminotransferase inhibitor, suppresses infantile spasms (IS) in the rat multiple-hit model will be made on December 3, 2011 at the American Epilepsy Society's 65th Annual Meeting (AES) to be held December 2-6, 2011 at the Baltimore Convention Center in Baltimore, Maryland.
The read more
To see the headquarters in Google Street View &trade, drag this yellow guy: 
over to the red pointer: 
